Consistently, losartan treatment or shRNA-mediated receptor silencing significantly reduced tumor burden in an immunodeficient xenograft model, suggesting a potential role for targeting AGTR1 in LAM and other manifestations of TSC. This evidence concerns the gene AGTR1 and neoplasm.